What the Clinical Guidelines Say About Nutrients and Depression
Several independent bodies have reviewed the evidence for nutrients in depression, and they converge on nutrients used alongside existing treatment. The 2022 WFSBP and CANMAT clinician guidelines give adjunctive omega-3 their strongest rating for any nutrient in unipolar depression, and a systematic review in the American Journal of Psychiatry concluded that current evidence supports the adjunctive use of SAMe, methylfolate and omega-3 with antidepressants.
Independent reviews converge on adjunctive use
Guidelines
Systematic Reviews
Meta-Reviews
Which bodies have reviewed this evidence?
Four are worth knowing. The World Federation of Societies of Biological Psychiatry and the Canadian Network for Mood and Anxiety Treatments published joint clinician guidelines on nutraceuticals and phytoceuticals in psychiatric disorders in 2022. [1] The American Journal of Psychiatry published a systematic review and meta-analyses of adjunctive nutraceuticals for depression. [2] The International Society for Nutritional Psychiatry Research published practice guidelines on omega-3 fatty acids in major depressive disorder in 2019. [3] And World Psychiatry, the highest-impact journal in the field, published a meta-review of thirty-three meta-analyses covering 10,951 people. [4]
What do they agree on?
That the strongest evidence concerns nutrients added to existing treatment, and that omega-3 leads it. The WFSBP and CANMAT guidelines give adjunctive omega-3 fatty acids their strongest rating for any nutrient in unipolar depression. [1] The World Psychiatry meta-review names eicosapentaenoic acid specifically as the nutrient carrying the strongest evidence in depression. [4] The American Journal of Psychiatry review concluded that current evidence supports the adjunctive use of SAMe, methylfolate and omega-3 with antidepressants to reduce depressive symptoms, and found primarily positive results in replicated studies for all three. [2] A guideline, a systematic review and an independent meta-review converging on the same set of nutrients is worth considerably more than any one of them alone.
How much does the form and dose matter?
A great deal, and this is the practical substance of what these documents say. Doses used in trials are often considerably higher than those in general-purpose supplements, i.e. 1 to 2 g a day of EPA and 15 mg a day of methylfolate in the studies that found benefit. [2][5] The specific form matters too, since the omega-3 trials that found benefit generally used formulations in which EPA predominates, and folate given in its already-active form does not depend on the conversion step that folic acid does. [2] Comparing products on total content alone will therefore mislead.
What does this mean in practice?
Guidelines describe what has been studied and how strongly; they do not decide anything for an individual. The evidence they summarise concerns nutrients used alongside existing treatment rather than instead of it, which is why a doctor’s involvement matters, and why every source on this page is linked in full below so anyone can read them directly. All four are freely available.
Where Hedonia sits
Hedonia provides the three nutrients this literature converges on, i.e. EPA omega-3, L-methylfolate and SAMe, at doses drawn from the trials that found benefit. It is a medical food for the dietary management of the nutritional requirements associated with depression, intended for use under medical supervision alongside a physician-directed treatment plan. The rationale for combining the three, rather than using any of them alone, is set out in a 2024 review in Nutrients. [6]
Watch this explained
[0:02] Look at the back of many supplement bottles, and you’ll find a long list.
[0:06] More must mean better.
[0:08] Right?
[0:09] Not necessarily.
[0:11] Hedonia is built around three nutrients.
[0:13] SAMe, L-methylfolate, and EPA, the short list is deliberate.
[0:19] So why these three?
[0:20] And what does the research actually tell us?
[0:23] First, a quick bit of context.
[0:25] In the United States, Hedonia is formulated and marketed as a medical food.
[0:30] It tells us a specific category of food intended for the dietary management of a condition
[0:35] with distinctive nutritional requirements under a doctor’s supervision.
[0:39] It is not a drug or an ordinary dietary supplement.
[0:42] And it is not an antidepressant.
[0:45] Hedonia does not replace medication or therapy.
[0:48] The condition here is major depressive disorder.
[0:51] So let’s take each nutrient in turn separating a plausible biological explanation from what
[0:56] the research has actually shown.
[0:58] First, SAMe.
[1:00] The full name is S-adenosyl-L-methionine, which is why almost everyone just calls it SAMe.
[1:06] Your body already makes it.
[1:08] Think of SAMe as a chemical courier.
[1:10] It carries a small unit called a methyl group and passes it on.
[1:14] That handover is called methylation.
[1:16] Methylation happens throughout the body.
[1:18] It supports many different reactions, including some involved in brain chemistry.
[1:24] SAMe has been studied in depression for decades, both alone and alongside antidepressants.
[1:29] Some studies suggest a benefit.
[1:31] Others do not.
[1:33] Many are small or use different formulations.
[1:37] So the fairest summary is this.
[1:39] Long studied, biologically interesting.
[1:42] But not settled.
[1:44] Next, L-methylfolate.
[1:46] Folate is Vitamin B9.
[1:48] But in the body it moves through several forms linked by a series of steps.
[1:53] One of those steps involves an enzyme called MTHFR.
[1:58] Common gene variants can make this step less efficient.
[2:01] Less efficient does not mean switched off.
[2:03] People with these variants can still process folate.
[2:06] L-methylfolate is already downstream of that step.
[2:09] It is also the main form of folate circulating in the blood.
[2:13] Why does that matter?
[2:14] In some studies, low folate status has been associated with a poorer response to antidepressants.
[2:20] That is an association.
[2:22] It does not prove that one causes the other, but it gave research as a reason to test L-methyl
[2:26] filate as an add-on.
[2:28] Some findings have been encouraging.
[2:30] Overall, though, the evidence remains limited.
[2:33] Third, EPA.
[2:35] EPA is a long chain omega-3 fatty acid, usually mentioned alongside DHA.
[2:42] Both become part of cell membranes.
[2:44] But that is only part of the story.
[2:46] They also feed into signaling pathways, including pathways involved in inflammation, and in
[2:51] depression research, EPA and DHA have not always behaved in the same way.
[2:58] Some analyses find a more consistent signal from formulations rich in EPA.
[3:03] Not in every trial, and certainly not a guarantee of benefit for any one person, but enough to
[3:08] explain the focus on EPA here.
[3:11] Now for the honest bit, a plausible mechanism is not clinical proof.
[3:17] Studies can make biology look wonderfully neat.
[3:20] Real people and real clinical trials rarely are.
[3:25] Studies can be small, results disagree, and conclusions can change as better evidence arrives.
[3:31] There is another distinction worth keeping clear.
[3:34] Each nutrient has been studied in depression.
[3:36] That is not the same as a clinical trial of the finished Hedonia combination.
[3:41] There is a scientific reason for each ingredient.
[3:43] There is published research behind each one, and uncertainty remains.
[3:48] Hedonia is one nutritional part of a wider, doctor-led plan, alongside whatever medication
[3:54] therapy or other medical care person needs.
[3:57] Hedonia is formulated and marketed in the United States as a medical food for the dietary
[4:02] management of nutritional deficiencies associated with depression for use under a doctor’s supervision.
[4:08] The research is linked below so you can examine the evidence for yourself rather than simply
[4:13] taking our word for it.
References
- Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the WFSBP and CANMAT Taskforce. World J Biol Psychiatry. 2022;23(6):424-455. PMID 35311615. PubMed
- Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry. 2016;173(6):575-587. PMID 27113121. PubMed
- Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, et al. International Society for Nutritional Psychiatry Research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom. 2019;88(5):263-273. PMID 31480057. PubMed
- Firth J, Teasdale SB, Allott K, Siskind D, Marx W, Cotter J, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18(3):308-324. Open access
- Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression. Am J Psychiatry. 2012;169(12):1267-1274. PMID 23212058. PubMed
- Tobin D, Vuckovic A, Sarris J. Targeting divergent pathways in the nutritional management of depression. Nutrients. 2024;16(16):2806. PMID 39203943. Open access